These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 24173660)

  • 1. A qualitative/quantitative approach for the detection of 37 tryptamine-derived designer drugs, 5 β-carbolines, ibogaine, and yohimbine in human urine and plasma using standard urine screening and multi-analyte approaches.
    Meyer MR; Caspar A; Brandt SD; Maurer HH
    Anal Bioanal Chem; 2014 Jan; 406(1):225-37. PubMed ID: 24173660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of new designer drugs in post-mortem blood using high-resolution mass spectrometry.
    Pasin D; Bidny S; Fu S
    J Anal Toxicol; 2015 Apr; 39(3):163-71. PubMed ID: 25552261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liquid chromatography-atmospheric pressure ionization electrospray mass spectrometry determination of "hallucinogenic designer drugs" in urine of consumers.
    Pichini S; Pujadas M; Marchei E; Pellegrini M; Fiz J; Pacifici R; Zuccaro P; Farré M; de la Torre R
    J Pharm Biomed Anal; 2008 Jun; 47(2):335-42. PubMed ID: 18262381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A general screening and confirmation approach to the analysis of designer tryptamines and phenethylamines in blood and urine using GC-EI-MS and HPLC-electrospray-MS.
    Vorce SP; Sklerov JH
    J Anal Toxicol; 2004 Sep; 28(6):407-10. PubMed ID: 15516287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of simultaneous gas chromatography-mass spectrometric and liquid chromatography-electrospray ionization mass spectrometric determination method for the new designer drugs, N-benzylpiperazine (BZP), 1-(3-trifluoromethylphenyl)piperazine (TFMPP) and their main metabolites in urine.
    Tsutsumi H; Katagi M; Miki A; Shima N; Kamata T; Nishikawa M; Nakajima K; Tsuchihashi H
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 May; 819(2):315-22. PubMed ID: 15833296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-detection of corticosteroids in sports doping and veterinary control using high-resolution liquid chromatography/time-of-flight mass spectrometry.
    Touber ME; van Engelen MC; Georgakopoulus C; van Rhijn JA; Nielen MW
    Anal Chim Acta; 2007 Mar; 586(1-2):137-46. PubMed ID: 17386705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LC-MS/MS screening method for designer amphetamines, tryptamines, and piperazines in serum.
    Wohlfarth A; Weinmann W; Dresen S
    Anal Bioanal Chem; 2010 Apr; 396(7):2403-14. PubMed ID: 20069283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous determination of four designer drugs and their major metabolites by liquid chromatography-mass spectrometry.
    Chen X
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Jun; 992():1-7. PubMed ID: 25939091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitive hydrophilic interaction liquid chromatography/tandem mass spectrometry method for rapid detection, quantification and confirmation of cathinone-derived designer drugs for doping control in equine plasma.
    Li X; Uboh CE; Soma LR; Liu Y; Guan F; Aurand CR; Bell DS; You Y; Chen J; Maylin GA
    Rapid Commun Mass Spectrom; 2014 Jan; 28(2):217-29. PubMed ID: 24338970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urine testing for designer steroids by liquid chromatography with androgen bioassay detection and electrospray quadrupole time-of-flight mass spectrometry identification.
    Nielen MW; Bovee TF; van Engelen MC; Rutgers P; Hamers AR; van Rhijn JH; Hoogenboom LR
    Anal Chem; 2006 Jan; 78(2):424-31. PubMed ID: 16408923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection and quantification of new designer drugs in human blood: Part 2 - Designer cathinones.
    Ammann D; McLaren JM; Gerostamoulos D; Beyer J
    J Anal Toxicol; 2012 Jul; 36(6):381-9. PubMed ID: 22593565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs of abuse screening in urine as part of a metabolite-based LC-MSn screening concept.
    Wissenbach DK; Meyer MR; Remane D; Philipp AA; Weber AA; Maurer HH
    Anal Bioanal Chem; 2011 Jul; 400(10):3481-9. PubMed ID: 21533799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of 32 cathinone derivatives and other designer drugs in serum by comprehensive LC-QQQ-MS/MS analysis.
    Swortwood MJ; Boland DM; DeCaprio AP
    Anal Bioanal Chem; 2013 Feb; 405(4):1383-97. PubMed ID: 23180084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid chromatography-electrospray mass spectrometry determination of ibogaine and noribogaine in human plasma and whole blood. Application to a poisoning involving Tabernanthe iboga root.
    Kontrimaviciūte V; Breton H; Mathieu O; Mathieu-Daudé JC; Bressolle FM
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Nov; 843(2):131-41. PubMed ID: 16798116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection and validated quantification of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, tadalafil, and 2 of their metabolites in human blood plasma by LC-MS/MS--application to forensic and therapeutic drug monitoring cases.
    Rust KY; Wilkens H; Kaiser R; Bregel D; Wilske J; Kraemer T
    Ther Drug Monit; 2012 Dec; 34(6):729-35. PubMed ID: 23128911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LC-MS analysis of trimethoxyamphetamine designer drugs (TMA series) from urine samples.
    Nieddu M; Boatto G; Pirisi MA; Azara E; Marchetti M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 May; 867(1):126-30. PubMed ID: 18417429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of 30 synthetic cannabinoids in serum by liquid chromatography-electrospray ionization tandem mass spectrometry after liquid-liquid extraction.
    Kneisel S; Auwärter V
    J Mass Spectrom; 2012 Jul; 47(7):825-35. PubMed ID: 22791249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-residue analysis of eight thioamphetamine designer drugs in human urine by liquid chromatography/tandem mass spectrometry.
    Nieddu M; Boatto G; Pirisi MA; Baralla E
    Rapid Commun Mass Spectrom; 2009 Oct; 23(19):3051-6. PubMed ID: 19705383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid chromatography/tandem mass spectrometry methods for quantitation of mevalonic acid in human plasma and urine: method validation, demonstration of using a surrogate analyte, and demonstration of unacceptable matrix effect in spite of use of a stable isotope analog internal standard.
    Jemal M; Schuster A; Whigan DB
    Rapid Commun Mass Spectrom; 2003; 17(15):1723-34. PubMed ID: 12872277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for and validated quantification of phenethylamine-type designer drugs and mescaline in human blood plasma by gas chromatography/mass spectrometry.
    Habrdova V; Peters FT; Theobald DS; Maurer HH
    J Mass Spectrom; 2005 Jun; 40(6):785-95. PubMed ID: 15827969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.